Thompson Siegel & Walmsley LLC Increases Stock Holdings in Baxter International Inc. (NYSE:BAX)

Thompson Siegel & Walmsley LLC grew its position in Baxter International Inc. (NYSE:BAX - Free Report) by 35.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,548,215 shares of the medical instruments supplier's stock after buying an additional 662,042 shares during the quarter. Baxter International accounts for approximately 1.2% of Thompson Siegel & Walmsley LLC's holdings, making the stock its 20th biggest holding. Thompson Siegel & Walmsley LLC owned 0.50% of Baxter International worth $74,306,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the company. CKW Financial Group increased its position in shares of Baxter International by 19.3% in the fourth quarter. CKW Financial Group now owns 2,625 shares of the medical instruments supplier's stock valued at $77,000 after buying an additional 425 shares in the last quarter. LRI Investments LLC increased its position in shares of Baxter International by 60.8% in the third quarter. LRI Investments LLC now owns 1,560 shares of the medical instruments supplier's stock valued at $59,000 after buying an additional 590 shares in the last quarter. Riverview Trust Co increased its position in shares of Baxter International by 5,488.2% in the fourth quarter. Riverview Trust Co now owns 950 shares of the medical instruments supplier's stock valued at $28,000 after buying an additional 933 shares in the last quarter. Farther Finance Advisors LLC boosted its stake in shares of Baxter International by 61.2% during the fourth quarter. Farther Finance Advisors LLC now owns 4,060 shares of the medical instruments supplier's stock valued at $118,000 after acquiring an additional 1,541 shares during the last quarter. Finally, Bruce G. Allen Investments LLC boosted its stake in shares of Baxter International by 247.3% during the fourth quarter. Bruce G. Allen Investments LLC now owns 2,622 shares of the medical instruments supplier's stock valued at $76,000 after acquiring an additional 1,867 shares during the last quarter. Hedge funds and other institutional investors own 90.19% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. The Goldman Sachs Group assumed coverage on Baxter International in a research note on Wednesday, February 26th. They set a "buy" rating and a $42.00 price objective on the stock. Argus upgraded Baxter International from a "hold" rating to a "buy" rating in a report on Monday, February 24th. Barclays raised their target price on Baxter International from $39.00 to $41.00 and gave the company an "overweight" rating in a report on Monday. JPMorgan Chase & Co. dropped their target price on Baxter International from $38.00 to $36.00 and set a "neutral" rating on the stock in a report on Friday, February 21st. Finally, Citigroup dropped their target price on Baxter International from $37.00 to $35.00 and set a "neutral" rating on the stock in a report on Wednesday, December 11th. One research analyst has rated the stock with a sell rating, five have given a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $38.56.

Remove Ads

Baxter International Price Performance

BAX stock opened at $34.34 on Thursday. The company has a market capitalization of $17.57 billion, a PE ratio of -26.83, a P/E/G ratio of 0.93 and a beta of 0.60. The stock's 50 day moving average is $32.25 and its two-hundred day moving average is $34.02. The company has a quick ratio of 1.09, a current ratio of 1.43 and a debt-to-equity ratio of 1.31. Baxter International Inc. has a 52-week low of $28.34 and a 52-week high of $43.99.

Baxter International (NYSE:BAX - Get Free Report) last issued its earnings results on Thursday, February 20th. The medical instruments supplier reported $0.58 EPS for the quarter, topping the consensus estimate of $0.52 by $0.06. The company had revenue of $2.75 billion during the quarter, compared to analyst estimates of $2.67 billion. Baxter International had a positive return on equity of 16.67% and a negative net margin of 5.05%. Analysts predict that Baxter International Inc. will post 2.48 earnings per share for the current fiscal year.

Baxter International Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 1st. Investors of record on Friday, February 28th will be given a dividend of $0.17 per share. The ex-dividend date of this dividend is Friday, February 28th. This represents a $0.68 dividend on an annualized basis and a yield of 1.98%. Baxter International's dividend payout ratio is currently -53.13%.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.